Why ChemoCentryx Shares Crashed 19.1% Today
Shock waves from a competitor's stumble sent the clinical-stage biotech's shares reeling.
ChemoCentryx
CCXI
CCXI
$8.53
-$0.17
0.0%
BATS BZX Real Time Price as of June 24, 2019, 4:00 p.m.
View Interactive CCXI Charts
Chemocentryx Inc. is a biopharmaceutical company focused on discovering developing and commercializing orally-administered therapeutics to treat autoimmune diseases inflammatory disorders and cancer.
News & Analysis: ChemoCentryx
ChemoCentryx Inc (CCXI) Q1 2019 Earnings Call Transcript
CCXI earnings call for the period ending March 31, 2019.
ChemoCentryx (CCXI) Q4 2018 Earnings Conference Call Transcript
CCXI earnings call for the period ending December 31, 2018.
ChemoCentryx (CCXI) Q4 2017 Earnings Conference Call Transcript
CCXI earnings call for the period ending December 31, 2017
Here's Why ChemoCentryx Rose as Much as 53.5% Today
The tiny biopharma stock is cruising on today's news. Does it deserve the pop?
Why ChemoCentryx Inc's Shares Shot 60% Higher Today
Is this meaningful? Or just another movement?
Keep an Eye on Ligand, Medivation, ChemoCentryx, and Teva Today
Ligand Pharmaceuticals, ChemoCentryx, Medivation, and Teva could make health care headlines today. Here's why.
This Week in Biotech
The buddy system works well for three companies this week while three others take a dive following uninspiring clinical-stage news.
3 Horrendous Health-Care Stocks This Week
The good, bad, and the ugly of health-care stocks this week -- but hold the good.
Does ChemoCentryx Have a Platform Problem?
Development obstacles are mounting for this emerging biotech. Is its therapeutic focus turning into a liability?
